Dr. Halland Chen, M.D.

Dr. Halland Chen, MD, is the Chief Medical Innovation Officer and a Medical Advisory Board member for GLP-1.com. He is a physician specializing in longevity medicine, regenerative medicine, NAD therapy, stem cell therapy, functional medicine, and anti aging protocols. Dr. Chen earned his medical degree from the University of Miami Miller School of Medicine and completed additional training at the Albert Einstein College of Medicine.

Dr. Chen's clinical practice is built around the principle that cutting edge medical innovation can extend both the quality and duration of human health. His expertise spans a wide range of advanced therapeutic modalities, from peptide protocols and NAD+ infusion therapy to stem cell treatments and metabolic optimization strategies. This forward looking approach to medicine gives him deep insight into how GLP-1 receptor agonist therapies fit within the broader landscape of longevity and regenerative health.

As Chief Medical Innovation Officer and Medical Advisory Board member for GLP-1.com, Dr. Chen provides strategic clinical leadership that ensures the platform stays at the forefront of evidence based weight management and metabolic health content. His combined expertise in regenerative medicine and pharmaceutical innovation helps GLP-1.com deliver authoritative, clinically rigorous content to patients exploring GLP-1 therapy.